and answer queries on asthma and doping, Royal Decree 641/2009 of the 17th of April, BOE 8/5/2009, that regulated doping control processes says, "All athletes with a license to participate in official state competitions may be selected at any time to undergo tests during competitions or outside competitions". No comments.

References

- Drobnic F. La información desinformada: el asma en los deportistas de elite. De Maimónides a los Juegos Olímpicos. Arch Bronconeumol. 2001;37:364-5.
- http://www.wada-ama.org/en/Science-Medicine/TUE/ (accessedd December 2009).
 Naranjo Orellana J, Centeno Prada RA, Carranza Márquez MD. Use of beta2 agonists
- in sport: are the present criteria right?. Br J Sports Med. 2006;40:363-6.

 4. Bergés R, Segura J, Ventura R, Fitch KD, Morton AR, Farré M, et al. Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin Chem. 2000;46:1365-75.

- Roig M, Bergés R, Ventura R, Fitch KD, Morton AR, Segura J. Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;768:315-24.
- 6. Drobnic F. Los agonistas adrenérgicos B2 y su influencia en el rendimiento físico. Archivos de Bronconeumología. 1997;33:136-42.

Franchek Drobnica,b

- ^bGIRSANE (Grup d' Investigació en el Rendiment i la Salut de l'Alt Nivell Esportiu), Sant Cugat del Vallés, Barcelona, Spain
- ^aDepartamento de Fisiología del Deporte del CAR, Servicios Médicos del FC Barcelona, Barcelona, Spain

E-mail address: drobnic@car.edu

Mortality in Lung Cancer and COPD

Mortalidad en cáncer de pulmón y en enfermedad pulmonar obstructiva crónica

To the Editor:

In the interesting article by Abal et al¹ entitled «Lung Cancer and COPD: a frequent association» a broad clinical cohort of 996 patients over a period of 5 years is assessed. The first conclusion is relevant and current: The association of both pathological conditions is frequent, and the most frequent histological diagnosis is squamous carcinoma; however, it is more difficult to take in its second and significant conclusion. The survival of patients with lung cancer and COPD is greater than that of patients with lung cancer without COPD. This second finding seems contrary to all that has been published so far with reference to comorbidities of both conditions, and we make reference to the excellent review in these same pages by Díez Herranz² in 2001 and other more recent sources.³⁻⁵ It has even been reported that greater mortality has been seen in non-smokers with both conditions. The authors themselves are surprised and theorize in the «Discussion» about a possible diagnostic bias and about the fact that patients with COPD may be diagnosed with lung cancer before patients without COPD. Probably, a repeat analysis of the data would make it possible to reconsider said conclusion, based on a view of the Kaplan-Meier survival curves (Fig. 1) and a significant difference of p = 0.016 obtained using the Mantel-Haenszel test (logarithmic ranges). Maybe due to the baseline differences between both groups (Table 4), it would be more appropriate to use an adjusted Cox regression model for the significant variables in the bivariate analysis, including sex, age, smoking and stage of lung cancer or other variables. The time in months/years between COPD diagnosis and cancer diagnosis could also be modelled. Finally, although in «Methods» section it is indicated that diagnosis and COPD classification were carried out according to GOLD directives, it would be interesting to repeat the same model eliminating those COPD cases diagnosed without spirometry.

Nevertheless, as Brody and Spira³ state, most smokers never will develop either COPD or lung cancer, it is important to investigate this relationship in detail.

References

- Abal Arca J, Parente Lamelas I, Almazán Ortega R, Blanco Pérez J, Toubes Navarro ME, Marcos Velázquez P. Cáncer de pulmón y EPOC: una asociación frecuente. Arch Bronconeumol. 2009;45:502-7.
- Díez-Herranz J. Enfermedad pulmonar obstructiva crónica y cáncer de pulmón:implicaciones prácticas. Arch Bronconeumol. 2001;37:240-7.
- Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3:535-7.
- Kiri VA, Soriano JB, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J 2009 Sep 15. pii: pcrj-2009-02-0021. doi:10.4104/pcrj.2009.00048. [Epub ahead of print].
- Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med. 2009;103:85-90.
- Turner MC, Chen Y, Krewski D, Calle EE, Thun MJ. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007;176:285-90.

Joan B. Soriano

Programa de Epidemiología e Investigación Clínica, Fundación Caubet-CIMERA Illes Balears, Hospital Joan March, Bunyola, Mallorca, Spain

E-mail address: jbsoriano@caubet-cimera.es

Response by the Authors

Respuesta de los autores

To the Editor:

We thank Joan B.Soriano for the interest shown in our recently published article. We consider his comments are relevant and correct, and the suggestions undoubtedly improve on the original.

Following his advice, we have re-analysed the data eliminating the 16 COPD patients without spirometry. The Kaplan-Meier survival curves continue to be significantly different between patients with and without COPD, being greater in COPD patients (p = 0.006).

Indeed, as the author points out in his letter, and this is seen in the results, an adjusted Cox regression model was used for significant variables in the bivariate analysis, although only stage and treatment remained in the final model. COPD, on the contrary, was not statistically significant. In the discussion we commented on the